In a study by Gaggini et al. it was found that the plasma irisin levels, measured by enzyme-linked immunosorbent assay (ELISA), did not differ between hepatocellular carcinoma (HCC) patients and the control group [93]. This evidence concerns the gene FNDC5 and hepatocellular carcinoma.